+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Sjogren's Syndrome - Epidemiology Forecast to 2029

  • ID: 5187227
  • Report
  • October 2020
  • Region: Global
  • 31 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 2
Summary

Sjögren’s syndrome (SS) is a chronic autoimmune disease, characterized by immune cells attacking and destroying the glands that produce tears and saliva (NIH, 2019). It results in two major clinical manifestations: keratoconjunctivitis sicca (dry eyes) and xerostomia (dry mouth), more broadly known as sicca syndrome (Arthritis Foundation, 2019). It can be classified into two types, primary and secondary SS. Primary SS (pSS) is seen in the absence of any other autoimmune disease (Salliot et al., 2007). Those most at risk of disease are women ages 40 and older (Johns Hopkins University, 2020).

Through an extensive literature review and analysis of recent and historical data, the publisher epidemiologists have provided the most reliable and up-to-date forecast for SS in the 7MM. The publisher epidemiologists performed a literature review, in both English and country-specific languages, to provide the most thorough search for SS data. The forecast provides detailed, clinically relevant segmentations of the SS population, with pSS prevalence, sSS prevalence, and ESSDAI proportions included in all markets.

The publisher epidemiologists have forecast the diagnosed prevalent cases of SS in the 7MM to increase from 1,630,861 in 2019, to 1,753,781 in 2029, with an annual growth rate (AGR) of 0.75%. In 2019, the publisher epidemiologists estimated 1,111,294 diagnosed prevalent cases of pSS and 519,567 diagnosed prevalent cases of sSS. For systemic involvement of pSS defined by ESSDAI, the publisher epidemiologists showed across the 7MM, the largest proportion of cases reported low-activity (ESSDAI< 5) (70.20%) and the smallest proportion of cases reporting high-activity (ESSDAI≥14) (5.59%). The publisher epidemiologists predict that if other markets identify and address gaps in the diagnosis of SS as well as advocate for more dedicated SS research, similar to the UK, the rate of diagnosis will increase over time.

Scope
  • The Sjögren’s Syndrome Epidemiology Report provides an overview of the risk factors, comorbidities, and global trends of Sjögren’s Syndrome (SS) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • The report includes a 10-year epidemiological forecast for diagnosed prevalent cases of pSS and sSS, with pSS segmented by sex and by age (18-29 years and for ages 30 years and older by 10-year age groups up to 80 years and older). Diagnosed prevalent cases of pSS are further segmented by systemic activity level using the ESSDAI classification.
  • The SS epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in SS
Reasons to Buy

The SS Epidemiology series will allow you to -
  • Develop business strategies by understanding the trends shaping and driving the global SS markets.
  • Quantify patient populations in the global SS markets to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for SS therapeutics in each of the markets covered.
  • Understand magnitude of systemic involvement of pSS defined by ESSDAI.
Note: Product cover images may vary from those shown
2 of 2
1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Sjögren’s Syndrome: Executive Summary
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Reports

3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.3.1 Diagnosed Prevalence of SS (%)
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Sources Not Used
3.4.3 Forecast Assumptions and Methods
3.5 Epidemiological Forecast for SS (2019-2029)
3.5.1 Diagnosed Prevalent Cases of pSS
3.5.2 Diagnosed Prevalent Cases of sSS
3.5.3 Age-Specific Diagnosed Prevalent Cases of pSS
3.5.4 Sex-Specific Diagnosed Prevalent Cases of pSS
3.5.5 Diagnosed Prevalent Cases of pSS by ESSDAI
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 Limitations of Analysis
3.6.3 Strengths of Analysis

4 Appendix
4.1 Bibliography
4.2 About the Authors
4.2.1 Epidemiologist
4.2.2 Reviewers
4.2.3 Director of Epidemiology and Global Director of Therapy Analysis and Epidemiology
4.2.4 Global Head and EVP of Healthcare Operations and Strategy
4.3 About the Publisher
4.4 Contact
4.5 Disclaimer

List of Tables
Table 1: Summary of Newly Added Data Types
Table 2: Summary of Updated Data Types
Table 3: Risk Factors and Comorbidities for SS

List of Figures
Figure 1: 7MM, Diagnosed Prevalent Cases of SS, Men and Women, Ages ≥18 Years, 2019 and 2029
Figure 2: 7MM, Diagnosed Prevalence of SS (%), Men and Women, ≥18 Years, 2019
Figure 3: 7MM, Sources Used and Not Used for the Diagnosed Prevalence of pSS
Figure 4: 7MM, Sources Used for the Diagnosed Prevalence of sSS
Figure 5: 7MM, Sources Used for the Diagnosed Prevalence of pSS by ESSDAI
Figure 6: 7MM, Diagnosed Prevalent Cases of pSS, Men and Women, Ages ≥18 Years, 2019
Figure 7: 7MM, Diagnosed Prevalent Cases of sSS, Men and Women, Ages ≥18 Years, 2019
Figure 8: 7MM, Age-Specific Diagnosed Prevalent Cases of pSS, Men and Women, Ages ≥18 Years, 2019
Figure 9: 7MM, Sex-Specific Diagnosed Prevalent Cases of pSS, Men and Women, Ages ≥18 Years, 2019
Figure 10: 7MM, Diagnosed Prevalent Cases of pSS by ESSDAI, Men and Women, Ages ≥18 Years, 2019
Note: Product cover images may vary from those shown
Adroll
adroll